DSM-Firmenich, CH1216478797

DSM-Firmenich stock: Jefferies cuts rating from Buy to Hold

Published on 11/16/2026 at 17:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Jefferies cut its rating on DSM-Firmenich stock from Buy to Hold on November 11, citing limited room for further valuation expansion. The call adds a cautious analyst signal.

Analyst caution weighs on valuation

  • Jefferies lowered DSM-Firmenich from Buy to Hold on November 11.
  • The bank cited limited room for further valuation expansion.
  • The group continues to benefit from strong positions in fragrance, flavors and nutrition.
DSM-Firmenich, CH1216478797, Illustration mit AI erstellt.

Jefferies downgraded DSM-Firmenich from Buy to Hold on November 11, citing limited scope for further valuation expansion. The analyst action gives investors a more cautious view of the shares after a strong run in 2026.

Jefferies turns more cautious

Investing.com reported that Jefferies viewed DSM-Firmenich's absolute and relative valuation multiples as above their historical averages. The bank nevertheless described the portfolio as high quality, highlighting the Perfumery & Beauty division and the Taste, Texture & Health business.

Jefferies also pointed to structural growth opportunities in Health, Nutrition & Care, while noting that parts of the portfolio are less differentiated. The assessment therefore combines a constructive view of the businesses with a more restrained expectation for further multiple expansion.

Growth remains part of the case

The report said DSM-Firmenich delivered double-digit fine-fragrance growth through the first half of 2026. Jefferies estimated fourth-quarter adjusted EBITDA at 443 million euros, broadly in line with consensus, and forecast 2027 adjusted EBITDA of 2.026 billion euros, about 2% above the cited Visible Alpha consensus.

For investors, the rating change shifts attention from operating momentum to the price paid for that growth. The next focus is whether the group's financial performance can support the valuation premium identified by Jefferies.

Latest Lang & Schwarz quote

DSM-Firmenich stock traded at 104.53 euros on Lang & Schwarz at 17:07 CET on Monday, November 16, 2026.

DSM-Firmenich company details

  • Company: DSM-Firmenich AG
  • ISIN: CH1216478797
  • Lang & Schwarz quote: 104.53 euros on November 16, 2026 at 17:07 CET
  • Rating action: Jefferies moved the rating from Buy to Hold on November 11, 2026

For broader market context, see Current market reports.

More news and analyses on DSM-Firmenich stock.

Disclaimer...
en | CH1216478797 | DSM-FIRMENICH | boerse | 70521763 | bgmi